F2R and Hematuria: Addition of either PAR‐1 inhibitor or agonists did not significantly modify the hematuric effects of dabigatran (two‐way ANOVA of changes in hematuria with the addition of SCH79797, p = 0.3141; two‐way ANOVA of changes in hematuria with addition of TFLLR‐NH2, p = 0.4578), Figure 2a,b.